| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
8,290,000 |
| Market
Cap: |
21.06(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.24 - $4.38 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lumos Pharma is a clinical-stage biopharmaceutical company. Co. is engaged in developing its clinical program and focused on identifying, acquiring, developing, and commercialization products and new therapies for people with rare diseases. Co.'s pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders where injectable recombinant human growth hormone is approved. Co.'s small-molecule product candidates, indoximod, NLG802 (a prodrug of indoximod) and NLG919 (a direct IDO1 enzymatic inhibitor) are indoleamine-2, 3-dioxygenase pathway inhibitors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
12,789 |
| Total Buy Value |
$0 |
$0 |
$0 |
$96,371 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
7 |
| Total Shares Sold |
2,214 |
2,652 |
6,059 |
10,074 |
| Total Sell Value |
$6,144 |
$7,472 |
$18,391 |
$48,860 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
2 |
3 |
6 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hawkins Richard J |
Chief Executive Officer |
• • – |
2023-02-01 |
4 |
A |
$3.52 |
$15,840 |
D/D |
4,500 |
752,743 |
|
- |
|
| Mckew John C. |
Chief Scientific Officer |
• – – |
2023-02-01 |
4 |
D |
$3.52 |
$725 |
D/D |
(206) |
26,896 |
|
- |
|
| Mckew John C. |
Chief Scientific Officer |
• – – |
2023-02-01 |
4 |
A |
$3.52 |
$7,040 |
D/D |
2,000 |
27,102 |
|
- |
|
| Schuchart Aaron |
Chief Business Officer |
• – – |
2023-02-01 |
4 |
D |
$3.52 |
$366 |
D/D |
(104) |
5,381 |
|
- |
|
| Schuchart Aaron |
Chief Business Officer |
• – – |
2023-02-01 |
4 |
A |
$3.52 |
$3,520 |
D/D |
1,000 |
5,485 |
|
- |
|
| Lawley Lori D |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
D |
$3.52 |
$401 |
D/D |
(114) |
11,505 |
|
- |
|
| Lawley Lori D |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
A |
$3.52 |
$3,520 |
D/D |
1,000 |
11,619 |
|
- |
|
| Powers Bradley J |
General Counsel |
• – – |
2023-02-01 |
4 |
D |
$3.52 |
$461 |
D/D |
(131) |
6,331 |
|
- |
|
| Powers Bradley J |
General Counsel |
• – – |
2023-02-01 |
4 |
A |
$3.52 |
$3,168 |
D/D |
900 |
6,462 |
|
- |
|
| Mccracken Joseph S |
Director |
– • – |
2022-11-16 |
4 |
B |
$5.03 |
$20,120 |
D/D |
4,000 |
15,721 |
2.39 |
-31% |
|
| Hawkins Richard J |
Chief Executive Officer |
• • – |
2022-09-23 |
4 |
B |
$8.80 |
$1,830 |
I/I |
208 |
4,469 |
2.58 |
-62% |
|
| Hawkins Richard J |
Chief Executive Officer |
• • – |
2022-09-21 |
4 |
B |
$8.84 |
$19,572 |
I/I |
2,214 |
4,261 |
2.58 |
-61% |
|
| Hawkins Richard J |
Chief Executive Officer |
• • – |
2022-09-20 |
4 |
B |
$8.75 |
$13,178 |
I/I |
1,506 |
2,047 |
2.58 |
-60% |
|
| Hawkins Richard J |
Chief Executive Officer |
• • – |
2022-09-19 |
4 |
B |
$8.65 |
$4,680 |
I/I |
541 |
541 |
2.58 |
-60% |
|
| Karpf David B |
Chief Medical Officer |
• – – |
2022-09-01 |
4 |
D |
$8.53 |
$4,862 |
D/D |
(570) |
7,330 |
|
- |
|
| Raffin Thomas A. |
Director |
– • – |
2022-08-25 |
4 |
B |
$8.46 |
$9,729 |
D/D |
1,150 |
9,406 |
2.39 |
-53% |
|
| Mccracken Joseph S |
Director |
– • – |
2022-08-25 |
4 |
B |
$8.60 |
$27,262 |
D/D |
3,170 |
11,721 |
2.39 |
-53% |
|
| Mckew John C. |
Chief Scientific Officer |
• – – |
2022-08-02 |
4 |
AS |
$8.11 |
$27,631 |
D/D |
(3,407) |
24,602 |
|
-60% |
|
| Mckew John C. |
Chief Scientific Officer |
• – – |
2022-08-01 |
4 |
D |
$8.17 |
$13,015 |
D/D |
(1,593) |
28,009 |
|
- |
|
| Lawley Lori D |
Chief Financial Officer |
• – – |
2022-08-01 |
4 |
D |
$8.17 |
$1,871 |
D/D |
(229) |
10,119 |
|
- |
|
| Mckew John C. |
Chief Scientific Officer |
• – – |
2022-06-06 |
4 |
AS |
$7.62 |
$1,288 |
D/D |
(169) |
29,102 |
|
22% |
|
| Mckew John C. |
Chief Scientific Officer |
• – – |
2022-04-05 |
4 |
AS |
$8.32 |
$18,420 |
D/D |
(2,214) |
29,271 |
|
10% |
|
| Mckew John C. |
Chief Scientific Officer |
• – – |
2022-04-01 |
4 |
D |
$9.23 |
$9,562 |
D/D |
(1,036) |
31,485 |
|
- |
|
| Hawkins Richard J |
Chief Executive Officer |
• • – |
2022-04-01 |
4 |
D |
$9.23 |
$13,531 |
D/D |
(1,466) |
748,243 |
|
- |
|
| Powers Bradley J |
General Counsel |
• – – |
2022-04-01 |
4 |
D |
$9.23 |
$3,157 |
D/D |
(342) |
5,562 |
|
- |
|
473 Records found
|
|
Page 2 of 19 |
|
|
0.09 (3.42%) 
